Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.68 USD | -0.74% | -6.32% | +6.16% |
Business Summary
Number of employees: 587
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody-based Therapies
100.0
%
| 1,616 | 100.0 % | 86 | 100.0 % | -94.67% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1,616 | 100.0 % | 86 | 100.0 % | -94.67% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Sung Lee
DFI | Director of Finance/CFO | 53 | 23-03-26 |
Jennifer Towne
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 05 |
Aine M. Hanly
CTO | Chief Tech/Sci/R&D Officer | 54 | 21-02-28 |
Phil Pang
CTO | Chief Tech/Sci/R&D Officer | 49 | 16-11-30 |
George Scangos
BRD | Director/Board Member | 75 | 16-12-31 |
Richard Lepke
IRC | Investor Relations Contact | - | Dec. 31 |
Sasha Ellis
PRN | Corporate Officer/Principal | - | 23-07-09 |
Lynne Krummen
PRN | Corporate Officer/Principal | - | 17-12-31 |
Corporate Officer/Principal | 73 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Sigal
BRD | Director/Board Member | 72 | 20-07-01 |
Robert Perez
BRD | Director/Board Member | 59 | 16-12-31 |
Robert More
BRD | Director/Board Member | 56 | 16-08-31 |
Phillip Sharp
BRD | Director/Board Member | 79 | 16-12-31 |
Robert Nelsen
FOU | Founder | 60 | 16-04-06 |
Vicki Sato
CHM | Chairman | 75 | 16-11-30 |
George Scangos
BRD | Director/Board Member | 75 | 16-12-31 |
Director/Board Member | 48 | 19-08-31 | |
Janet Napolitano
BRD | Director/Board Member | 65 | 20-08-27 |
Chief Executive Officer | 56 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 135,032,268 | 115,298,095 ( 85.39 %) | 0 | 85.39 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.16% | 1.44B | |
+9.72% | 46.21B | |
+35.14% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |
- Stock
- Equities
- Stock Vir Biotechnology, Inc. - Nasdaq
- Company Vir Biotechnology, Inc.